Following the capacity increase of its syngas production facility in Bay City, Texas, USA, the chemical company Oxea is in the last stages of completion of a feasibility study of additional downstream plant expansion projects.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International